Inhibikase Therapeutics (IKT) Revenue (2020 - 2023)
Inhibikase Therapeutics (IKT) posted quarterly Revenue of $1.0 for Q4 2023, down 100.0% year-over-year from $63566.0 in Q4 2022, and down 100.0% quarter-over-quarter from $79569.0 in Q3 2023.
Inhibikase Therapeutics (IKT) Revenue (2020 - 2023) Analysis & Trends
Inhibikase Therapeutics (IKT) has reported Revenue for 4 consecutive years, with $1.0 the latest figure, recorded in Q4 2023.
- In Q4 2023, Revenue fell 100.0% year-over-year to $1.0; the TTM figure through Sep 2024 stood at $1.0 (down 100.0% YoY), while the FY2023 annual figure was $260501.0, up 111.03% from the prior year.
- Revenue slipped to $1.0 in Q4 2023 per IKT's latest filing, from $79569.0 in the prior quarter.
- Across five years, Revenue topped out at $1.4 million in Q1 2021 and bottomed at $1.0 in Q4 2023.
- Historically, Revenue has averaged $261438.4 across 4 years, with a median of $72045.0 in 2023.
- Annual changes were most pronounced in 2022 — Revenue soared 3169.86% — and 2023, when it slumped 100.0%.
- Inhibikase Therapeutics' Revenue stood at $170416.0 in 2020, then tumbled by 98.86% to $1944.0 in 2021, then jumped by 3169.86% to $63566.0 in 2022, then plunged by 100.0% to $1.0 in 2023.
- Business Quant data shows IKT's Revenue at $1.0 in Q4 2023, $79569.0 in Q3 2023, and $116410.0 in Q2 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.33 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 4.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.56 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.71 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3,001.92 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 674.14 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.29 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 425.49 Mn |
| 10 | Inhibikase Therapeutics | 420.72 Mn | 261.70 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 1.00 |
| Sep 30, 2023 | 79,569.00 |
| Jun 30, 2023 | 116,410.00 |
| Mar 31, 2023 | 64,521.00 |
| Dec 31, 2022 | 63,566.00 |
| Sep 30, 2022 | 7,291.00 |
| Jun 30, 2022 | 6,552.00 |
| Mar 31, 2022 | 46,031.00 |
| Dec 31, 2021 | 1,944.00 |
| Sep 30, 2021 | 328,459.00 |
| Jun 30, 2021 | 1.36 Mn |
| Mar 31, 2021 | 1.41 Mn |
| Dec 31, 2020 | 170,416.00 |
| Sep 30, 2020 | 37,680.00 |
| Jun 30, 2020 | 219,585.00 |
| Mar 31, 2020 | 270,787.00 |